Business Wire

Everen Group Appoints Robert Foskey as President & CEO

6.8.2024 22:10:00 EEST | Business Wire | Press release

Share

The Everen Group, a group of leading energy insurance companies, is pleased to announce the appointment of Robert Foskey as the new President & Chief Executive Officer, effective August 5, 2024. Mr. Foskey brings a wealth of experience and a proven track record of success with the Everen Group and is set to lead the company into its next phase of growth and innovation.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240806098310/en/

Robert Foskey Appointed President & CEO of Everen Group (Photo: Business Wire)

Over the past 17 years with the Everen Group, Mr. Foskey has demonstrated exceptional leadership and strategic vision, in his capacity as the Group Chief Actuary for 15 years and most recently as the Chief Operating Officer of Everen Limited. He has overseen key operational improvements and driven significant growth. Mr. Foskey has a deep understanding of the Group’s mission and values, making him the ideal choice for the role of CEO.

Mr. Foskey’s selection is the culmination of a robust, year-long leadership succession search process led by the Board. “We are extremely pleased to appoint Rob as Group CEO,” said John Weisner, Chair of the Board of Everen Limited. “His contributions as Chief Actuary and COO have been invaluable, and the Board is confident he will continue to propel the Everen Group forward with the same dedication and inspiration. The Board would also like to thank Bertil Olsson for his contributions to the Everen Group as CEO over the past nine years.”

John Talarico, Chair of the Board of Everen Specialty Ltd., added, “The Board unanimously agree that Rob is the ideal leader for the Everen Group. His in-depth knowledge of our operations and commitment to our organization will ensure a seamless transition and continued success.”

Commenting on his appointment, Mr. Foskey said, “I am honored and excited to take on the role of Group CEO. It has been a privilege to be a part of the Everen Group and to lead Everen Limited as COO. I want to thank the Board for its confidence as I step into this role. I look forward to working with our talented leadership team and employees as we continue to innovate and deliver consistent value to our shareholders and customers and advance the Group’s position as leaders in the global insurance industry. I am committed to fulfilling our mission and values and enhancing our culture through teamwork, collaboration and transparency.”

About Everen Group:

The Everen Group includes two distinct operating companies providing complementary products: Everen and Everen Specialty. Everen is the largest energy insurance mutual company in the world, operating for over 50 years and acting as a pure mutual owned by its member shareholders. Its underwriting is 100% supported by its own balance sheet with no third party capital and it offers up to $450 million of per occurrence limits. Everen Specialty is an industry owned commercial (re)insurer offering property and casualty insurance and reinsurance for members and non-members. Everen Specialty also have a subsidiary, OCIL Specialty, Ltd (OSL), writing U.S. surplus lines business through OSL Insurance Services (OISI), a managing general agent based in Houston, Texas.

For further information about the companies, please visit Everen.bm and EverenSpecialty.bm.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240806098310/en/

Contacts

For inquiries regarding this press release, please contact Karyn Peixoto, VP,
Human Resources & Administration on hr@everengroup.bm

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release

Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

SES Publishes FY2025 EU Taxonomy Restatement31.7.2026 08:30:00 EEST | Press release

SES today published a restatement of its FY2025 EU Taxonomy (Article 8) disclosure. The restatement updates the FY2025 EU Taxonomy disclosure included in the 2025 Annual Report and supersedes the previously published disclosure. The FY2025 EU Taxonomy Restatement is available on the SES website: https://www.ses.com/sites/ses_v2/files/investor-files/2026-07/EU_Taxonomy_Report_Restatement_2025.pdf Follow us on: X | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where they are. With integrated multi-orbit satellites and our global terrestrial network, we deliver resilient, seamless connectivity and the highest quality video content to those shaping what’s next. Following our Intelsat acquisition, we now offer more than 100 years of combined global industry l

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye